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ABSTRACT: 
 
Purpose: To report the clinical outcomes of adalimumab therapy in cases of Birdshot 
chorioretinitis (BCR) with cystoid macular edema (CME) refractory to conventional 
immunotherapy. Methods: Retrospective case series of three BCR patients treated with 
adalimumab for refractory CME. The main outcome measure was central subfield 
thickness (CST) on optical coherence tomography. Any patients treated with local 
steroids and / or receiving systemic steroids higher than 40 mg prednisolone daily during 
adalimumab therapy were excluded. Results: At baseline, all patients were receiving 
systemic corticosteroids and two second-line immunosuppresive agents. The mean 
duration of treatment with adalimumab was 31.2 months (range: 17.2-52). The mean CST 
was 327 ± 112.7 μm (mean ± SD) at baseline and 256.2 ± 39.7 μm at 6 months and 235.5 
± 32.5 μm at 12 months. Adalimumab permitted cessation or reduction in the daily dose 
of oral prednisolone plus withdrawal of a second line agent in all patients. Conclusions: 
In these patients adalimumab was effective in the treatment of refractory CME. 
 
KEYWORDS: Birdshot chorioretinopathy, Birdshot chorioretinitis, Adalimumab, Anti-
tumour necrosis factor alpha (anti-TNF), Cystoid macular edema 
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INTRODUCTION 
 
Birdshot chorioretinopathy (BCR) is a rare posterior uveitis involving the choroid and 
retinal vasculature that is strongly associated with the human leucocyte antigen HLA-
A29.[1] It is an isolated ocular disorder characterized by the presence of multiple 
choroidal hypopigmented inflammatory lesions. The diagnosis remains clinical and the 
natural history is typically chronic resulting in a progressive decline in retinal function on 
visual field and electroretinogram testing.[2] Chronic cystoid macular edema (CME) is 
the predominant cause of central vision loss.[3-5] Early and aggressive 
immunosuppressive treatment is recommended to preserve vision,[6,7] with the standard 
of care being systemic corticosteroids plus conventional second line immunosuppresive 
drugs such as anti-proliferative agents and T cell inhibitors. In refractory cases biologic 
agents such as intravenous immunoglobulins, [8] daclizumab, [9] tocilizumab, [10] and 
infliximab [11] have all been tried with varying success. 
 
The recent VISUAL trials have provided level 1 evidence supporting the clinical efficacy 
of adalimumab, a humanized monoclonal antibody targeted against tumor necrosis 
(TNF)-alpha, in reducing the frequency of inflammatory relapse for uveitis patients with 
a diverse range of uveitic diagnoses.[12,13] This included BCR, but a sub-group analysis 
was not reported and the inclusion criteria were not limited to refractory disease. Specific 
outcomes for BCR including electrodiagnostic tests (EDTs) were also not measured. In 
usual clinical practice, funding for high cost interventions such as adalimumab in rare 
conditions is often limited to patients who fail to achieve disease remission with the 
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standard of care, and in this context retrospective case series remain valuable in guiding 
treatment decisions. We are therefore reporting the clinical outcome of adalimumab 
therapy in cases of BCR with refractory CME. 
 
METHODS 
 
The medical records of all patients with CME associated with BCR treated with 
adalimumab in our center were reviewed. Any patients that received local steroid therapy 
(intravitreal or periocular) and/or systemic corticosteroid higher than prednisolone 40mg 
daily during adalimumab treatment were excluded. Data retrieved included age, gender, 
time since diagnosis and systemic immunosuppressive therapy at the start of adalimumab 
treatment. The best corrected visual acuity (BCVA), central subfoveal thickness (CST) 
determined by optical coherence tomography (OCT), and changes in immunosuppressive 
therapy regime were recorded for the duration of adalimumab therapy. The main outcome 
measure was the effect on CST. Wider retinal function was evaluated by analysis of serial 
EDTs performed before and during adalimumab treatment. 
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RESULTS  
 
Three caucasian patients with bilateral BCR and CME refractory to conventional 
systemic immunosuppressive therapy were included in the study. All the patients were 
HLA-A29 positive. Two patients were female. The mean age at diagnosis of BCR was 
49.9 ± 5.2 (mean ± SD) years (range: 46.6-55.9). The mean age at the time of starting 
adalimumab was 52.9 ± 6.1 (mean ± SD) years (range: 47.7-59.6), with a mean time from 
diagnosis to initiation of adalimumab of 3.0 ± 1.6 years (mean ± SD) (range: 1.2 - 4.1). 
Prior to adalimumab treatment, each patient received oral prednisone (all ≥10mg/day) 
and two second-line immunosuppressive agents (Table 1). None had previously received 
treatment with a biologic agent. All received adalimumab 40mg subcutaneously every 2 
weeks with a mean duration of treatment of 31.2 months (range: 24.4-52). Table 1 
summarizes the demographic data, systemic treatment and visual acuity at baseline and at 
the end of follow up. 
 
1. OCT Central Subfoveal Thickness 
Figure 1 shows the evolution of the CST for each patient from the start of 
immunosuppressive therapy to the end of follow up. Key therapeutic changes are 
highlighted. The mean CST for all patients (6 eyes) was 327 ± 112.7 μm (mean ± SD) at 
baseline and 256.2 ± 39.7 μm (mean ± SD) and 235.5 ± 32.5 μm (mean ± SD) after 6 and 
12 months of adalimumab therapy (Fig. 2). 
 
2. Visual Acuity 
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BCVA improved in 4 eyes (3 patients) and remained stable in 2 eyes (2 patients) from 
introduction of adalimumab to the end of follow-up. (Table 1) 
 
3. Electrodiagnostic test (EDTs) 
Serial ISCEV standard dark-adapted (DA) 3.0 (combined rod-cone) and light adapted 
(LA) 3.0 flicker (30Hz) ERGs were performed. Amplitudes of both A and B waves of the 
DA 3.0 response, 30 Hz flicker and latency of the 30 Hz flicker were analyzed over time 
and the average pre- and post-drug measurements were compared. There was an 
improvement in the amplitude of A and B waves of the DA 3.0 response in 4 of the 6 
eyes post-treatment, an improvement in the amplitude of the 30 Hz flicker in 4 of the 6 
eyes and an improvement in the latency in 5 of the 6 eyes post-treatment. Table 2 
summarizes the results for each patient and each parameter pre- and post-treatment. 
 
4. Changes to Systemic Treatment 
At the end of follow up, adequate control of inflammation and CME permitted reduction 
of the systemic immunosuppressive therapy regimes in all 3 patients. Oral corticosteroid 
treatment was withdrawn in one patient and reduced in the other two patients to ≤7.5mg 
daily (Figure 1). 
 
DISCUSSION 
 
There is a strong and increasing evidence base in favour of anti-TNF alpha therapies for 
the treatment of uveitis, exemplified by the recent VISUAL trials.[12,13] However, a 
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dearth of disease specific data remains. For refractory BCR, a previous retrospective case 
series of patients treated with infliximab (a non-humanised, chimeric anti-TNF-alpha 
monoclonal antibody) concluded that this was effective in controlling disease in 89% of 
cases at 12 months.[11] This included a good response in 7 eyes in 5 patients with 
bilateral refractory BCR associated CME. Our results for adalimumab treatment endorse 
this observation, which suggests that rather than being drug specific effect, treatment 
benefit is attributable to the class of anti-TNF-alpha therapies as a whole. Furthermore, in 
all three cases, adalimumab led to an improvement in at least one electrodiagnostic 
parameter, a reduction in concomitant oral prednisone therapy and the number of second-
line immunosuppressive treatments used. These limited data therefore support the use of 
adalimumab in rare cases of BCR with CME which is refractory to treatment with >10mg 
prednisone daily and 2 conventional second-line immunosuppressive agents. 
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FIGURE LEYENDS 
 
Fig 1 Diagram showing the central subfoveal thickness (CST), including the changes in 
systemic or ocular treatment, for each patient during the follow-up. There is an 
approximate interval of 6 months’ time between vertical lines 
 
Fig. 2 Mean central subfoveal thickness (CST) at the differences time intervals after 
treatment 
 
